TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data

Table 1

Main characteristics of eligible studies.

Author (yrs)	Cases	Age; (mean yrs)	HG I/II (III/IV)	Metastatic disease	Treatment	PCR exons	Deaths in 2 years, (%)	Chemotherapy response (criteria)
Yokoyama et al. (1998) [23]	17	15	(8/7)	2	NC + surgery	4–8	1 (6)	6/14 (S-K)
Radig et al. (1998) [24]	18	34	10/8	0	Surgery	4–8	2 (17)	NR
Goto et al. (1998) [12]	32	16	(23/9)	8	NC + surgery	MS	14 (44)	3/31 (N90)
Tsuchiya et al. (2000) [13]	27	15	NR	2	NC + surgery	5–9	11 (41)	NR
Kawaguchi et al. (2002) [25]	23	55	(8/15)	NR	Surgery	5–9	12 (52)	NR
Patiño-García et al. (2003) [26]	41	14	NR	8	NR	5–8	7 (18)	22/41 (N90)
Entz-Werle et al. (2003) [27]	54	13	(43/11)	6	NC + surgery	MS	4 (7)	30/53 (Huvos)
Richter et al. (2013) [28]	17	34	NR	NR	Surgery	5–9	5 (31)	3/17 (Huvos)

Note. Exons: exons of the TP53 gene analyzed by polymerase chain reaction.
: number; yrs: years; HG: histological grades; NC: neoadjuvant chemotherapy; Huvos: histological response based on the Huvos grading system; NR: not reported; N90: histological response based on >90% tumor cell necrosis; PCR: polymerase chain reaction; S-K: histological response based on Salzer-Kuntschik’s classification; MS: microsatellite primers.